Intervenn’s noninvasive ovarian cancer test to hit market this fall
A noninvasive diagnostic test to help distinguish ovarian cancer from benign pelvic masses will be available this fall. GlycoKnow Ovarian received a proprietary laboratory…
Gynecological cancer
Projections show uterine cancer cases, mortality rate, on rise in US
The number of uterine cancer cases and related deaths — the disease’s incidence and mortality rates — in the U.S. are expected to substantially rise…
Approval sought of relacorilant for platinum-resistant ovarian cancer
Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination with the standard chemotherapy agent…
CAR-T cell therapy for ovarian cancer enters next phase of testing
A Phase 1 clinical trial evaluating escalating doses of Anixa Biosciences’ experimental CAR T-cell therapy for recurrent ovarian cancer has begun dosing participants…
Trial of BAT8006 for form of ovarian cancer doses 1st patient
The first patient has been dosed in a Phase 3 trial testing the investigational therapy BAT8006 in people with platinum-resistant ovarian cancer, according to the…
Ovarian cancer immunotherapy found to boost immune response
IMNN-001, Imunon’s experimental immunotherapy for advanced ovarian cancer, boosts the body’s natural immune response by increasing levels of immune signaling proteins that aid in…
1st patient dosed in trial of Enhertu for HER2 endometrial cancer
A Phase 3 clinical trial of Enhertu, a therapy developed by Daiichi Sankyo and AstraZeneca, has begun dosing its first patient with…
Relacorilant delays ovarian cancer disease progression: Trial data
Relacorilant lowered the risk of disease progression and death by about 30% when used on top of standard chemotherapy in people with platinum-resistant ovarian cancer.
FDA fast tracks PHST001 as treatment for ovarian cancer
Pheast Therapeutics has received fast track designation from the U.S. Food and Drug Administration (FDA) for PHST001, its candidate treatment for ovarian cancer, a type…
Pembrolizumab improves survival outcomes in ovarian cancer trial
Treatment with pembrolizumab — an immune-modulating therapy sold for some cancers under the brand name Keytruda — improved survival among people with platinum-resistant ovarian cancer…
